Abbvie earnings were $6.3B for the trailing 12 months ending Jun 30, 2026, with 68.2% growth year over year. The latest ABBV earnings report on Jun 30, 2026 announced Q2 2026 earnings of $3.6B, up 419.9% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, ABBV reported annual earnings of $4.2B, with -1.2% growth. The next ABBV earnings date is Oct 30, 2026.
ABBV past earnings growth
How has ABBV's earnings growth performed historically?
On ABBV's earnings call on Jul 31, 2026, Abbvie (NYSE: ABBV) reported Q2 2026 earnings per share (EPS) of $2.04, up 292.31% year over year. Total ABBV earnings for the quarter were $3.61 billion. In the same quarter last year, Abbvie's earnings per share (EPS) was $0.52.
The next ABBV earnings call is Oct 30, 2026. Add ABBV to your watchlist to be reminded of Abbvie's next earnings date.
Is Abbvie profitable or losing money?
As of the last Abbvie earnings report, Abbvie is currently profitable. Abbvie's net profit (also called net income) for the twelve months ending Jun 30, 2026 was $6.31 billion, a 67.69% increase year over year.
What was ABBV's earnings growth in the past year?
As of Abbvie's earnings date in Jul 31, 2026, Abbvie's earnings has grown 68.25% year over year. This is 40.53 percentage points higher than the US Drug Manufacturers - General industry earnings growth rate of 27.71%. ABBV earnings in the past year totalled $6.31 billion.
What are Abbvie's earnings expectations?
The current EPS estimate for Abbvie's earnings report in Oct 30, 2026 is $3.86.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.